The latest company loans awarded by the North Carolina Biotechnology Center in the fourth quarter of FY 2016 bring to 189 the number of North Carolina bioscience companies that have received funding from the Center since its inception in 1984. The companies have received 276 loans totaling just under $34 million.

Subsequently those portfolio companies have raised almost $3.7 billion in additional funding from other sources including grants from disease foundations and federal agencies; angel and venture capital funding; and initial public stock offerings, according to the Center. That’s $108, on average, for every $1 the Center has loaned to them.

In the 2016 fiscal year, the companies raised $262 million in publicly announced follow-on funding from other sources. That figure doesn’t include un-announced funding events, such as acquisitions, by privately held companies.

During the last six months 20 portfolio companies raised nearly $68 million in follow-on funding, highlighted by G1 Therapeutics’ $47 million Series C financing. Other companies that received funding during the period include Advanced Animal Diagnostics, BioFluidica, Camras Vision, CivaTech Oncology, Entegrion, KeraNetics, Locus Biosciences, and T3D Therapeutics, each of which raised between $1 million and $3 million.

A roundup of NCBiotech loans and grants for the final quarter of the 2015-2016 fiscal year appears in an adjacent news story: